Precigen Q3 2021 Earnings Report
Key Takeaways
Precigen announced topline summary of the presentations planned for today’s 2021 R&D Day virtual event, showcasing clinical progress for Precigen’s UltraCAR-T platform and the AdenoVerse Immunotherapy platform. Initial data for PRGN-3005 and PRGN-3006 continue to demonstrate favorable safety profiles, dose-dependent expansion, and durable persistence.
50% objective response rate in relapsed or refractory acute myeloid leukemia patients treated with PRGN-3006.
40% objective response rate and 60% disease control rate in recurrent or metastatic human papilloma virus-associated cancer patients treated in the PRGN-2009 combination arm.
Preliminary PRGN-2012 Phase 1 data show encouraging clinical activity, including ongoing reduction/elimination of the need for surgical intervention.
PRGN-3005 and PRGN-3006 UltraCAR-T demonstrate favorable safety profiles with no dose-limiting toxicities or neurotoxicity, dose-dependent in vivo expansion and durable persistence.